Research advances in immunotherapy for prostate cancer
10.3969/j.issn.1009-8291.2025.08.001
- VernacularTitle:前列腺癌的免疫治疗研究进展
- Author:
Yuanjie NIU
1
;
Jianpeng YU
1
;
Keruo WANG
1
Author Information
1. 天津医科大学第二医院泌尿外科,天津 300211
- Publication Type:Journal Article
- Keywords:
prostate cancer;
immunotherapy;
cancer vaccine;
immune checkpoint inhibitor
- From:
Journal of Modern Urology
2025;30(8):635-641
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy has demonstrated significant efficacy in hematologic malignancies and certain solid tumors,but its efficacy for prostate cancer remains suboptimal.This is largely due to the immunosuppressive tumor microenvironment,which involves factors such as tumor heterogeneity,a paucity of infiltrating lymphocytes,and the absence of inflammatory features.Therefore,developing novel immunotherapeutic targets and combining multiple immunotherapy modalities to activate the host immune system and reverse the immunosuppressive tumor microenvironment are crucial for improving immunotherapy for prostate cancer.This review systematically summarizes the current research on prostate cancer immunotherapy,covering the challenges and advances of prostate cancer vaccines,the application of immune checkpoint inhibitors,targeted therapeutic strategies involving chimeric antigen receptor T cells,bispecific antibodies,and emerging strategies in prostate cancer immunotherapy.Furthermore,the review discusses the future directions for the development of prostate cancer immunotherapy.
